5-乙酰基-2,2-噻吩基 | 3515-18-2

• 物质功能分类: 医药中间体 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 双噻吩和低聚噻吩
• 中文名称: 5-乙酰基-2,2-噻吩基
• 中文别名: 3,4-二甲基噻吩
• 英文名称: 5-acetyl-2,2'-bithiophene
• 英文别名: 2-acetyl-5-(thien-2-yl)thiophene；1-(5-Thiophen-2-ylthiophen-2-yl)ethanone
• CAS: 3515-18-2
• 化学式: C₁₀H₈OS₂
• 分子量: 208.305
• InChiKey: GKGAOTYPISAEEK-UHFFFAOYSA-N

物化性质

• 熔点：
  109-114 °C
• 沸点：
  363.4±32.0 °C(Predicted)
• 密度：
  1.260±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  在常温常压下保持稳定，应避免与不相容的材料接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  73.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2934999090
• 储存条件：
  密封储存，宜存放在阴凉、干燥的库房中。冷藏时温度应保持在4°C。

SDS

Name:	5-Acetyl-2 2 -Bithienyl Material Safety Data Sheet
Synonym:	None Known
CAS:	3515-18-2

Section 1 - Chemical Product MSDS Name:5-Acetyl-2 2 -Bithienyl Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
3515-18-2	5-Acetyl-2,2'-Bithienyl	ca. 100	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a dry area. Keep refrigerated. (Store below 4C/39F.)

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 3515-18-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: yellowish
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 114 - 115 deg C @ 760 mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H8OS2
Molecular Weight: 208.30

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3515-18-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Acetyl-2,2'-Bithienyl - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 3515-18-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3515-18-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3515-18-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-乙酰基-2,2-噻吩基 在 ammonium hydroxide 硫酸 作用下， 以 乙醇 、 溶剂黄146 为溶剂， 反应 33.0h， 生成 2-[2,2']bithiophenyl-5-yl-quinoline-4-carboxylic acid
  参考文献：
  名称：

  Synthesis and antiviral activity of 2-[aryl(hetaryl)]quinoline-4-carboxylic acids

  摘要：

  DOI：

  10.1007/bf00758458
• 作为产物：
  描述：

  2,2'-联二噻吩 、 乙酸酐 在 磷酸 作用下， 反应 14.0h， 生成 5-乙酰基-2,2-噻吩基
  参考文献：
  名称：

  噻吩-2-基和噻吩基取代的吡嗪-2,3-二碳腈作为四取代氮杂酞菁锌的前体

  摘要：

  外围的噻吩-2-基取代基扩展了锌（II）氮杂酞菁（ZnAzaPc）的大环共轭，这是由于两个环系统之间存在共面性，并且观察到了红移的UV-Vis Q谱带。能量的降低对于各种应用是有利的。合成了在5位上被烷基噻吩-2-基或双噻吩基取代的吡嗪2,3,3-二腈，作为母体四取代ZnAzaPcs的前体，预计还会显示出红移的Q带。Zn（喹啉）2 Cl 2试剂用于一步环四聚。没有被二噻吩基取代的前体产生干净的反应，并且主要得到聚合物材料。获得了分别分别被5-乙基-噻吩-2-基和3,4-二甲基-噻吩-2-基四取代的两个ZnAzaPcs，收率为40-50％。对于两种四聚体的蓝绿色DMF溶液，在660 nm处有UV-Vis Q谱带，摩尔消光系数为111000和89000 M-1 cm-1。2D NMR方法应用于DMF-d7溶液的分析。两种化合物的1H NMR信号的部分重叠，表明存在聚集现象。另外，光谱中尖峰的广

  DOI：

  10.1016/j.poly.2013.02.017
• 作为试剂：
  描述：

  2-(2-adamantylidene)adamantane 在 5-乙酰基-2,2-噻吩基 、 氧气 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 金刚烷酮
  参考文献：
  名称：

  D'Auria, Maurizio; Mico, Antonella De; D'Onofrio, Franco, Journal of the Chemical Society. Perkin transactions I, 1987, p. 1777 - 1780

  摘要：

  DOI：

文献信息

• The first use of [PdBr2(imidazolidin-2-ylidene)(pyridine)] catalysts in the direct C-H bond arylation of C2-substituted furan and thiophene
  作者：Murat Kaloğlu、Nazan Kaloğlu、Namık Özdemir、İsmail Özdemir

  DOI：10.1007/s11164-021-04444-4

  日期：2021.7

  was determined by single-crystal X-ray diffraction study. The catalytic activities of all palladium complexes were evaluated in the direct C-H bond arylation of the 2-acetylfuran and 2-acetylthiophene with (hetero) aryl bromides and readily available and inexpensive aryl chlorides in presence of 1 mol% catalyst loading at 120 °C. Under the given conditions, (hetero)aryl halides were successfully applied

  摘要 ñ-杂环卡宾（NHC）连接的PEPPSI型钯络合物最近已用于杂芳烃的直接CH键芳基化。然而，在大多数已发表的著作中，已经使用了含有苯并咪唑和咪唑环的NHC配体，但是很少使用含有饱和咪唑啉环的NHC配体。因此，在这项研究中，合成了四种新的1,3-二取代的咪唑啉盐作为NHC配体前体，以及它们的四种新的PEPPSI型钯配合物。所有新化合物的结构均通过不同的光谱和分析技术进行了全面表征。钯配合物之一的更详细的结构表征是通过单晶X射线衍射研究确定的。在120℃下，负载1 mol％催化剂的条件下，在2-乙酰基呋喃和2-乙酰基噻吩与（杂）芳基溴化物和易得且廉价的芳基氯化物的直接CH键芳基化反应中，评估了所有钯配合物的催化活性。在给定的条件下，成功地使用了（杂）芳基卤化物作为芳基化试剂，以可接受的高收率获得了C5芳基化的呋喃和噻吩。 图形摘要
• Room-Temperature Suzuki-Miyaura Coupling of Heteroaryl Chlorides and Tosylates
  作者：Junfeng Yang、Sijia Liu、Jian-Feng Zheng、Jianrong Steve Zhou

  DOI：10.1002/ejoc.201200918

  日期：2012.11

  Suzuki–Miyaura coupling of heteroaryls is an important method for the preparation of compound libraries for medicinal chemistry and materials research. Although many catalysts have been developed, none of them have been generally applicable to the coupling reactions of heteroaryl chlorides and tosylates at room temperature. We discovered that a catalyst combination of Pd(OAc)2 and XPhos (2-dicyclohexylphosphanyl-2′

  杂芳基的 Suzuki-Miyaura 偶联是制备用于药物化学和材料研究的化合物库的重要方法。尽管已经开发了许多催化剂，但它们都没有普遍适用于杂芳基氯与甲苯磺酸酯在室温下的偶联反应。我们发现 Pd(OAc)2 和 XPhos（2-二环己基膦酰基-2',4',6'-三异丙基联苯）的催化剂组合可以有效地催化这些偶联。除了催化剂的选择，在含水醇溶剂中使用氢氧化物碱对于快速偶联也是必不可少的。这些条件促进了活性催化剂（XPhos）Pd0 的快速释放，并加速了催化循环中的金属转移。大多数杂芳基氯（31 个实例）和甲苯磺酸盐（17 个实例）的主要家族在室温下在几分钟到几小时内达到完全转化。该方法可以很容易地扩大规模以进行克级合成。此外，我们检查了整个反应中偶联伙伴的相对反应性。富电子杂芳基氯化物和甲苯磺酸盐的反应速度比缺电子杂芳基化合物慢，顺序为吲哚、吡咯呋喃、噻吩>吡啶。类似地，缺电子芳基硼酸的反应
• Synthesis ofC3-Symmetric Nano-Sized Polyaromatic Compounds by Trimerization and Suzuki−Miyaura Cross-Coupling Reactions
  作者：Sambasivarao Kotha、Dhurke Kashinath、Kakali Lahiri、Raghavan B. Sunoj

  DOI：10.1002/ejoc.200400257

  日期：2004.10

  Various C3-symmetric molecules were prepared by trimerization of acetyl aromatic compounds and subsequently coupled with various boronic acids under Pd0 catalysis conditions to generate oligoaryl/-heteroaryl C3-symmetric molecules. Several furan- and thiophene-containing star-shaped molecules were prepared by the use of Suzuki−Miyaura cross-coupling as a key step. Structural and conformational details

  通过乙酰芳族化合物的三聚反应制备了各种 C3 对称分子，随后在 PdO 催化条件下与各种硼酸偶联以生成低聚芳基/-杂芳基 C3 对称分子。通过使用 Suzuki-Miyaura 交叉偶联作为关键步骤，制备了几种含有呋喃和噻吩的星形分子。使用 AM1 方法通过半经验分子轨道理论探索结构和构象细节。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004)
• Synthesis of Quinoxaline-Linked Bis(Benzimidazolium) Salts and Their Catalytic Application in Palladium-Catalyzed Direct Arylation of Heteroarenes
  作者：Murat Kaloğlu、Mehmet Hanifi Şahan、Serpil Demir Düşünceli、İsmail Özdemir

  DOI：10.1007/s10562-021-03787-2

  日期：2022.7

  synthesized as bis-N-heterocyclic carbene (NHC) precursors. These bis(NHC) precursors were used as multidentate ligands for the construction of bi(hetero)aryls by palladium-catalyzed direct C-H activation process. The in situ prepared palladium complexes by mixtures of the Pd(OAc)2 and the bis(NHC) precursors were used as the catalyst for direct C-H activation of heteroarenes. These catalytic system exhibited

  摘要 在这项研究中，喹喔啉连接的双（苯并咪唑）盐被合成为双-N-杂环卡宾 (NHC) 前体。这些双 (NHC) 前体被用作多齿配体，用于通过钯催化的直接 CH 活化过程构建双 (杂) 芳基。通过Pd(OAc) 2和双(NHC)前体的混合物原位制备的钯配合物用作杂芳烃直接CH活化的催化剂。这些催化体系在具有多种（杂）芳基溴化物的五元杂芳烃的直接 CH 活化中表现出适度的催化活性。 图形摘要
• Medicinal thiophene compounds
  申请人：Industrial Technology Research Institute

  公开号：US05747525A1

  公开（公告）日：1998-05-05

  A method of treating tumor including administering to a subject an effective amount of a compound of the following formula: ##STR1## wherein m is 1-4; and each of A and B, independently, is H, C.sub.1-7 alkyl, C.sub.2-7 alkenyl, C.sub.2-7 alkynyl, (CH.sub.2).sub.n CHO, (CH.sub.2).sub.o COOH, C.sub.1-7 alkoxy, C.sub.2-7 alkoxyalkyl, C.sub.1-7 hydroxyalkyl, CN, NO.sub.2, halogen, CH(OR.sup.1).sub.2, CO.R.sup.1, NR.sup.2 R.sup.3 or its acid salt, CO.NR.sup.2 R.sup.3, CHR.sup.1 NR.sup.2 R.sup.3 or its acid salt, CH.dbd.NR.sup.2, C.tbd.CR.sup.4, CR.sup.1 .dbd.CR.sup.5 R.sup.6, CO.CH.dbd.CHR.sup.7, CH.dbd.CHR.sup.8, or COOR.sup.9 ; in which each of n and o, independently, is 0-4; R.sup.1 is C.sub.1-4 alkyl or C.sub.1-4 acyl; each of R.sup.2 and R.sup.3, independently, is H, C.sub.1-4 alkyl, or C.sub.1-4 hydroxyalkyl; R.sup.4 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, COR.sup.2, COOR.sup.10, C.sub.1-4 hydroxyalkyl or its acid ester or 2-tetrahydropyranyl ether, C.sub.1-4 dihydroxyalkyl or its acid ester or 2-tetrahydropyranyl ether, C.sub.1-4 halogenated alkyl; OR.sup.1, or NHR.sup.7 ; each of R.sup.5 and R.sup.6, independently, is H, CHO, COR.sup.1, COOH, COOR.sup.9, CN, or halogen; R.sup.7 is H, C.sub.1-4 alkyl, 2-thienyl, phenyl, mono-substituted phenyl, or di-substituted phenyl; R.sup.8 is COOR.sup.2, CO.CHO, C.sub.1-4 hydroxyalkyl or its acid ester or 2-tetrahydropyranyl ether; and R.sup.9 is H, C.sub.1-4 alkyl, phenyl, mono-substituted phenyl, di-substituted phenyl, or 2-thienyl.

  治疗肿瘤的方法包括向受试者施用以下式的化合物的有效量：##STR1## 其中m为1-4；A和B中的每一个独立地为H、C.sub.1-7烷基、C.sub.2-7烯基、C.sub.2-7炔基、(CH.sub.2).sub.nCHO、(CH.sub.2).sub.oCOOH、C.sub.1-7烷氧基、C.sub.2-7烷氧基烷基、C.sub.1-7羟基烷基、CN、NO.sub.2、卤素、CH(OR^1).sub.2、CO.R^1、NR^2R^3或其酸盐、CO.NR^2R^3、CHR^1NR^2R^3或其酸盐、CH.dbd.NR^2、C.tbd.CR^4、CR^1.dbd.CR^5R^6、CO.CH.dbd.CHR^7、CH.dbd.CHR^8或COOR^9；其中n和o中的每一个独立地为0-4；R^1为C.sub.1-4烷基或C.sub.1-4酰基；R^2和R^3中的每一个独立地为H、C.sub.1-4烷基或C.sub.1-4羟基烷基；R^4为H、C.sub.1-4烷基、C.sub.2-4烯基、COR^2、COOR^10、C.sub.1-4羟基烷基或其酸酯或2-四氢吡喃基醚、C.sub.1-4二羟基烷基或其酸酯或2-四氢吡喃基醚、C.sub.1-4卤代烷基；OR^1或NHR^7；R^5和R^6中的每一个独立地为H、CHO、COR^1、COOH、COOR^9、CN或卤素；R^7为H、C.sub.1-4烷基、2-噻吩基、苯基、单取代苯基或双取代苯基；R^8为COOR^2、CO.CHO、C.sub.1-4羟基烷基或其酸酯或2-四氢吡喃基醚；R^9为H、C.sub.1-4烷基、苯基、单取代苯基、双取代苯基或2-噻吩基。